目的评价那格列奈联合门冬胰岛素30(N30)治疗胰岛素控制不良的2型糖尿病(T2DM)的有效性和安全性。方法 40例T2DM患者均分为单用N30治疗(N组)和加用那格列奈治疗(NN组)。NN组在胰岛素治疗的基础上,于中餐前加服那格列奈120mg,疗程1个月。结果与N组相比,NN组中餐后血糖、糖化血红蛋白控制更理想,且低血糖反应少。结论对接受N30治疗而中餐后血糖仍不达标的T2DM患者,那格列奈是个良好的备选降糖药。 Objective To evaluate the efficacy and safety of nateglinide combined with insulin aspart 30 (N30) in the treatment of type 2 diabetes mellitus (T2DM) with poorly controlled insulin. Methods Forty patients with T2DM were divided into N30 group (N group) and nateglinide group (NN group). On the basis of insulin treatment, NN group received nateglinide 120 mg before Chinese food, and the course of treatment was 1 month. Results Compared with the N group, the NN group had better control of postprandial blood glucose and glycosylated hemoglobin and less hypoglycemic reaction. Conclusions Nateglinide is a good alternative hypoglycemic agent for T2DM patients who receive N30 treatment and whose postprandial blood glucose is still not satisfactory.